Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.

European journal of clinical pharmacology - 1 Jun 2018

Liu Shuaibing, Xue Ling, Shi Xiangfen, Sun Zhiyong, Zhu Zhenfeng, Zhang Xiaojian, Tian Xin

Abstract excerpt

BACKGROUND: Ticagrelor, the first reversible P2Y12 receptor antagonist, exhibits faster onset and offset of antiplatelet effects and more consistent platelet inhibition than clopidogrel in both healthy subjects and patients with stable coronary artery disease. OBJECTIVE: The objectives of this study were to establish a population pharmacokinetics (PK) and pharmacodynamics (PD) model of ticagrelor and to provide a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine
Share to Blood Platelets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Dose-Response Relationship, Drug

Share to Healthy Volunteers

Share to Platelet Aggregation

Share to Purinergic P2Y Receptor Antagonists

Share to Ticagrelor

Source

Identifiers

PMID: 29442148
DOI: 10.1007/s00228-018-2427-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.PMID 29442148Read ↗

The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population.Semantic proximity Read ↗

No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.Semantic proximity Read ↗

Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.Semantic proximity Read ↗

A systematic study to evaluate the safety of ticagrelor combined with aspirin in the treatment of PCI patients in Chinese population: A single nucleotide polymorphisms study.Semantic proximity Read ↗

Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.Semantic proximity Read ↗

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.Semantic proximity Read ↗

Population pharmacokinetics and hemorrhagic risk analysis of rivaroxaban in Chinese elderly patients with non-valvular atrial fibrillationSemantic proximity Read ↗

Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients.Semantic proximity Read ↗

CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel.Semantic proximity Read ↗

A physiologically-based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: an evaluation of CYP2C19 activitySemantic proximity Read ↗

Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers.Semantic proximity Read ↗

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.